Healthcare Realty Trust (HR) Reports Q2 Earnings: What Key Metrics Have to Say

Healthcare Realty Trust (HR) reported mixed Q2 2025 results, with revenue of $297.5 million representing a 6% year-over-year decline and marginally missing consensus estimates. While the company posted a positive EPS of $0.41, which exceeded analyst expectations, its diluted net earnings per share came in at a significant loss of $-0.45, substantially wider than the estimated $-0.07 loss. This performance, marked by declining rental and interest income, contributed to HR shares underperforming the broader market, returning -3.1% over the past month against the S&P 500's +2.7%.

Analysis

Healthcare Realty Trust (HR) reported a challenging second quarter for 2025, characterized by top-line erosion and conflicting profitability signals. Total revenue declined 6% year-over-year to $297.5 million, narrowly missing the Zacks Consensus Estimate. The core of this weakness stems from a 6.8% YoY fall in rental income to $287.07 million and a 10.8% drop in interest income, both of which also failed to meet analyst projections. While the company posted a headline EPS of $0.41, representing a 2.5% surprise, this is sharply contradicted by a significant diluted net loss of $0.45 per share, which was substantially worse than the estimated loss of $0.07. This discrepancy suggests the adjusted figure may mask underlying fundamental pressures. The stock's recent performance reflects these concerns, with shares returning -3.1% over the past month, lagging the S&P 500 composite's +2.7% gain and aligning with its neutral Zacks Rank #3 (Hold) status.

Key Decisions for Investors

• Investors should look past the headline EPS beat and focus on the deteriorating fundamentals, particularly the 6% revenue decline and the significant miss on GAAP diluted earnings per share.
• Given the YoY declines in the primary rental and interest income streams, it is critical to monitor for stabilization in these core metrics before considering a more bullish stance.
• The stock's recent market underperformance and the neutral 'Hold' rating suggest a cautious approach is warranted, as the report lacks a clear catalyst for near-term appreciation.